A dedicated program to boost complex generics, more transparency into the abbreviated new drug application review process, and clearer opportunities for communication with US Food and Drug Administrat
A dedicated program to boost complex generics, more transparency into the abbreviated new drug application review process, and clearer opportunities for communication with US Food and Drug Administrat
In the latest in a long line of legal decisions, Teva and Viatris have once again failed in their bid to knock out a key US patent shielding Janssen’s Invega Sustenna (paliperidone palmitate) once-mon
The US Food and Drug Administration will not revoke abbreviated new drug application approvals for generic versions of Vanda Pharmaceuticals ’ Hetlioz (tasimelteon) 20mg capsules held by Teva and